Phospho-VEGFR3 (Tyr1230) Antibody - #AF3676

>>赠JD卡 进行中>>
(6)   (4)  
产品: 磷酸化 VEGFR3 (Tyr1230) 抗体
货号: AF3676
描述: Rabbit polyclonal antibody to Phospho-VEGFR3 (Tyr1230)
应用: IHC IF/ICC
文献验证:
反应: Human, Mouse, Rat
蛋白号: P35916
RRID: AB_2846990

浏览相似产品>>

   规格 价格 库存
 100ul RMB¥ 2800 现货
 200ul RMB¥ 3800 现货

货期: 当天发货

联系销售
相关下载
MSDS
说明书
COA
实验方案
WB Handbook
IHC Protocol
IF/ICC Protocol

产品描述

来源:
Rabbit
应用:
IHC 1:50-1:200, IF/ICC 1:100-1:500
*The optimal dilutions should be determined by the end user.
*Tips:

WB: 适用于变性蛋白样本的免疫印迹检测. IHC: 适用于组织样本的石蜡(IHC-p)或冰冻(IHC-f)切片样本的免疫组化/荧光检测. IF/ICC: 适用于细胞样本的荧光检测. ELISA(peptide): 适用于抗原肽的ELISA检测.

反应:
Human, Mouse, Rat
克隆:
Polyclonal
特异性:
Phospho-VEGFR3 (Tyr1230) Antibody detects endogenous levels of VEGFR3 only when phosphorylated at Tyr1230.
RRID:
AB_2846990
引用格式: Affinity Biosciences Cat# AF3676, RRID:AB_2846990.
偶联:
Unconjugated.
纯化:
The antibody is from purified rabbit serum by affinity purification via sequential chromatography on phospho-peptide and non-phospho-peptide affinity columns.
保存:
Rabbit IgG in phosphate buffered saline , pH 7.4, 150mM NaCl, 0.02% sodium azide and 50% glycerol. Store at -20 °C. Stable for 12 months from date of receipt.
别名:

展开/折叠

EC 2.7.10.1; flt 4; FLT-4; FLT4; FLT41; Fms related tyrosine kinase 4; Fms-like tyrosine kinase 4; LMPH1A; PCL; Soluble VEGFR3 variant 1; Soluble VEGFR3 variant 2; Soluble VEGFR3 variant 3; Tyrosine protein kinase receptor FLT4; Tyrosine-protein kinase receptor FLT4; Vascular endothelial growth factor receptor 3; Vascular endothelial growth factor receptor 3 precursor; VEGF R3; VEGFR 3; VEGFR-3; VEGFR3; VGFR3_HUMAN;

抗原和靶标

免疫原:

A synthesized peptide derived from human VEGFR3 around the phosphorylation site of Tyr1230.

基因/基因ID:
FLT4(2324)

研究领域

· Cellular Processes > Cellular community - eukaryotes > Focal adhesion.   (View pathway)

· Environmental Information Processing > Signal transduction > MAPK signaling pathway.   (View pathway)

· Environmental Information Processing > Signal transduction > Ras signaling pathway.   (View pathway)

· Environmental Information Processing > Signal transduction > Rap1 signaling pathway.   (View pathway)

· Environmental Information Processing > Signaling molecules and interaction > Cytokine-cytokine receptor interaction.   (View pathway)

· Environmental Information Processing > Signal transduction > PI3K-Akt signaling pathway.   (View pathway)

· Human Diseases > Cancers: Overview > Pathways in cancer.   (View pathway)

· Human Diseases > Cancers: Specific types > Breast cancer.   (View pathway)

文献引用

1). Anti-lymphangiogenesis for boosting drug accumulation in tumors. Signal transduction and targeted therapy, 2024 (PubMed: 38616190) [IF=40.8]
2). Apelin-VEGF-C mRNA delivery as therapeutic for the treatment of secondary lymphedema. EMBO molecular medicine, 2024 (PubMed: 38177539) [IF=9.0]

Application: WB    Species: human    Sample:

Figure EV3. Stimulation of VEGFR3 phosphorylation by APLN. (A) Representatives phospho-VEGFR3/VEGFR3 and CCBE1 immunoblots of HDLEC treated with APLN +/− siRNA CCBE1. (B) Graphs represent quantification of CCBE1/GAPDH protein ratio from at least three independent experiments. Data represent mean ± SEM (n = 3 independent replicates) (*P 
3). Synergistic effects of mTOR inhibitors with VEGFR3 inhibitors on the interaction between TSC2-mutated cells and lymphatic endothelial cells. Science China. Life sciences, 2025 (PubMed: 39862344) [IF=8.0]
4). Discovery, Synthesis, and Evaluation of Novel Dual Inhibitors of a Vascular Endothelial Growth Factor Receptor and Poly(ADP-Ribose) Polymerase for BRCA Wild-Type Breast Cancer Therapy. Journal of Medicinal Chemistry, 2023 (PubMed: 37616488) [IF=6.8]
5). Discovery, Synthesis, and Evaluation of Highly Selective Vascular Endothelial Growth Factor Receptor 3 (VEGFR3) Inhibitor for the Potential Treatment of Metastatic Triple-Negative Breast Cancer. Journal of medicinal chemistry, 2021 (PubMed: 34351741) [IF=6.8]
6). A neuro-lymphatic communication guides lymphatic development by CXCL12 and CXCR4 signaling. Development (Cambridge, England), 2024 (PubMed: 39470100) [IF=4.6]

限制条款

产品的规格、报价、验证数据请以官网为准，官网链接：www.affbiotech.com | www.affbiotech.cn（简体中文）| www.affbiotech.jp（日本語）

产品的数据信息为Affinity所有，未经授权不得收集Affinity官网数据或资料用于商业用途，对抄袭产品数据的行为我们将保留诉诸法律的权利。

产品相关数据会因产品批次、产品检测情况随时调整，如您已订购该产品，请以订购时随货说明书为准，否则请以官网内容为准，官网内容有改动时恕不另行通知。

Affinity保证所销售产品均经过严格质量检测。如您购买的商品在规定时间内出现问题需要售后时，请您在Affinity官方渠道提交售后申请。

产品仅供科学研究使用。不用于诊断和治疗。 

产品未经授权不得转售。

Affinity Biosciences将不会对在使用我们的产品时可能发生的专利侵权或其他侵权行为负责。Affinity Biosciences, Affinity Biosciences标志和所有其他商标所有权归Affinity Biosciences LTD.